SCH 39166 hydrobromide
High affinity dopamine D1/D5 receptor antagonist; displays Ki values of 1.2, 2, 980, 5520, 80 and 731 nM for binding to D1, D5, D2, D4, 5-HT and α2a receptors, respectively.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 394.73. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.53 mL||12.67 mL||25.33 mL|
|5 mM||0.51 mL||2.53 mL||5.07 mL|
|10 mM||0.25 mL||1.27 mL||2.53 mL|
|50 mM||0.05 mL||0.25 mL||0.51 mL|
References are publications that support the products' biological activity.
Wu et al (2005) Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists. J.Med.Chem. 48 680 PMID: 15689153
Terry and Katz (1994) A comparison of the effects of the D1 receptor antagonists SCH 23390 and SCH 39166 on suppression of feeding behaviour by the D1 agonist SKF38393. Psychopharmacology 113 328 PMID: 7862841
McQuade et al (1991) In vivo binding of SCH 39166: a D-1 selective antagonist. J.Pharmacol.Exp.Ther. 257 42 PMID: 1826927
If you know of a relevant reference for SCH 39166 hydrobromide, please let us know.
View Related Products by Product Action
Keywords: SCH 39166 hydrobromide, supplier, High, affinity, D1/D5, receptor, antagonists, Dopamine, Receptors, dopaminergic, SCH39166, hydrobromide, Ecopipam, hydrobromide, D1, and, D5, Receptors, D1, and, D5, Receptors, Tocris Bioscience
2 Citations for SCH 39166 hydrobromide
Citations are publications that use Tocris products. Selected citations for SCH 39166 hydrobromide include:
Mizuta et al (2013) The dopamine D1 receptor is expressed and facilitates relaxation in airway smooth muscle. Am J Physiol Regul Integr Comp Physiol 14 89 PMID: 24004608
Zheng et al (2014) Attenuated dopaminergic tone in the paraventricular nucleus contributing to sympathoexcitation in rats with Type 2 diabetes. Nat Commun 306 R138 PMID: 24305061
Do you know of a great paper that uses SCH 39166 hydrobromide from Tocris? If so please let us know.
Reviews for SCH 39166 hydrobromide
There are currently no reviews for this product. Be the first to review SCH 39166 hydrobromide and earn rewards!
Have you used SCH 39166 hydrobromide?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.